188 related articles for article (PubMed ID: 33314259)
1. Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region.
Ye L; Chapman TP; Wen Z; Lin L; Qiu Y; Liu Z; Ran Z; Qian J; Wu K; Gao X; Hu P; Chen M; Travis SPL; Cao Q;
Aliment Pharmacol Ther; 2021 Feb; 53(3):390-399. PubMed ID: 33314259
[TBL] [Abstract][Full Text] [Related]
2. Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region.
Kumar P; Vuyyuru SK; Kante B; Sahu P; Goyal S; Madhu D; Jain S; Ranjan MK; Mundhra S; Golla R; Singh M; Virmani S; Gupta A; Yadav N; Kalaivani M; Sharma R; Das P; Makharia G; Kedia S; Ahuja V
Aliment Pharmacol Ther; 2022 Jun; 55(11):1431-1440. PubMed ID: 35229906
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?
Akyuz F; Cavus B; Iliaz R; Soyer OM; Ormeci A; Evirgen S; Onder S; Koksalan K; Keskin M; Karaca C; Demir K; Gulluoglu M; Cagatay T; Besisik F; Kaymakoglu S
Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):777-780. PubMed ID: 30964811
[TBL] [Abstract][Full Text] [Related]
4. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
[TBL] [Abstract][Full Text] [Related]
5. Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis.
Kurt OK; Kurt B; Talay F; Tug T; Soy M; Bes C; Hayran M
Wien Klin Wochenschr; 2013 Oct; 125(19-20):616-20. PubMed ID: 24061693
[TBL] [Abstract][Full Text] [Related]
6. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
[TBL] [Abstract][Full Text] [Related]
7. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.
Byun JM; Lee CK; Rhee SY; Kim HJ; Im JP; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
Scand J Gastroenterol; 2015 Mar; 50(3):312-20. PubMed ID: 25581784
[TBL] [Abstract][Full Text] [Related]
8. Screening for latent tuberculosis in patients with inflammatory bowel disease under antitumor necrosis factor: data from a Portuguese center.
Sousa M; Ladeira I; Ponte A; Fernandes C; Rodrigues A; Silva AP; Silva J; Gomes C; Afeto E; Carvalho J
Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1099-1102. PubMed ID: 31206406
[TBL] [Abstract][Full Text] [Related]
9. Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.
Abitbol Y; Laharie D; Cosnes J; Allez M; Nancey S; Amiot A; Aubourg A; Fumery M; Altwegg R; Michetti P; Chanteloup E; Seksik P; Baudry C; Flamant M; Bouguen G; Stefanescu C; Bourrier A; Bommelaer G; Dib N; Bigard MA; Viennot S; Hébuterne X; Gornet JM; Marteau P; Bouhnik Y; Abitbol V; Nahon S;
J Crohns Colitis; 2016 Oct; 10(10):1179-85. PubMed ID: 27402916
[TBL] [Abstract][Full Text] [Related]
10. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors.
Papay P; Primas C; Eser A; Novacek G; Winkler S; Frantal S; Angelberger S; Mikulits A; Dejaco C; Kazemi-Shirazi L; Vogelsang H; Reinisch W
Aliment Pharmacol Ther; 2012 Nov; 36(9):858-65. PubMed ID: 22978645
[TBL] [Abstract][Full Text] [Related]
11. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study.
Bermejo F; Algaba A; Chaparro M; Taxonera C; Garrido E; García-Arata I; Guerra I; Gisbert JP; Olivares D; de-la-Poza G; López-Sanromán A
Dig Liver Dis; 2013 Sep; 45(9):733-7. PubMed ID: 23587496
[TBL] [Abstract][Full Text] [Related]
12. Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study.
Calzada-Hernández J; Anton-López J; Bou-Torrent R; Iglesias-Jiménez E; Ricart-Campos S; Martín de Carpi J; ; Torrente-Segarra V; Sánchez-Manubens J; Giménez-Roca C; Rozas-Quesada L; Juncosa-Morros MT; Fortuny C; Noguera-Julian A
Pediatr Rheumatol Online J; 2015 Dec; 13():54. PubMed ID: 26635208
[TBL] [Abstract][Full Text] [Related]
13. The safety of vedolizumab in a patient with Crohn's disease who developed anti-TNF-alpha agent associated latent tuberculosis infection reactivation: A case report.
Sugiyama Y; Ueno N; Tachibana S; Kobayashi Y; Murakami Y; Sasaki T; Sakatani A; Takahashi K; Ando K; Kashima S; Moriichi K; Tanabe H; Okumura T; Fujiya M
Medicine (Baltimore); 2023 Jul; 102(28):e34331. PubMed ID: 37443475
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-α antagonist therapy.
Singanayagam A; Manalan K; Sridhar S; Molyneaux PL; Connell DW; George PM; Kindelerer A; Seneviratne S; Lalvani A; Wickremasinghe M; Kon OM
Thorax; 2013 Oct; 68(10):955-61. PubMed ID: 23976779
[TBL] [Abstract][Full Text] [Related]
15. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy.
Zabana Y; Domènech E; San Román AL; Beltrán B; Cabriada JL; Saro C; Araméndiz R; Ginard D; Hinojosa J; Gisbert JP; Mañosa M; Cabré E; Gassull MA
Inflamm Bowel Dis; 2008 Oct; 14(10):1387-91. PubMed ID: 18452206
[TBL] [Abstract][Full Text] [Related]
16. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening.
Jauregui-Amezaga A; Turon F; Ordás I; Gallego M; Feu F; Ricart E; Panés J
J Crohns Colitis; 2013 Apr; 7(3):208-12. PubMed ID: 22677117
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis Screening and Reactivation Among a National Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Antagonists.
Hou JK; Kramer JR; Richardson P; Sansgiry S; El-Serag HB
Inflamm Bowel Dis; 2017 Feb; 23(2):254-260. PubMed ID: 27997433
[TBL] [Abstract][Full Text] [Related]
18. The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-α blockers.
Byun JM; Lee CK; Rhee SY; Kim HJ; Kim JW; Shim JJ; Jang JY
J Korean Med Sci; 2015 Feb; 30(2):173-9. PubMed ID: 25653489
[TBL] [Abstract][Full Text] [Related]
19. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
Nisar MK; Rafiq A; Östör AJ
Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
[TBL] [Abstract][Full Text] [Related]
20. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.
Theis VS; Rhodes JM
Aliment Pharmacol Ther; 2008 Jan; 27(1):19-30. PubMed ID: 17944997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
